Navigation Links
Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
Date:11/3/2008

n, management's strategy, plans and objectives for future operations, plans and objectives for product development, plans and objectives for present and future clinical trials and results of such trials, plans and objectives for regulatory approval, litigation, intellectual property, product development, manufacturing plans and performance such as the anticipated growth in the monoclonal antibody market and our other target markets and projected growth in product sales, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the success of current and future collaborative relationships, the market acceptance of our products, our ability to compete with larger, better financed pharmaceutical and biotechnology companies, new approaches to the treatment of our targeted diseases, our expectation of incurring continued losses, our uncertainty of product revenues and profits, our ability to generate future revenues, our ability to raise additional capital to continue our drug development programs, the success of our clinical trials, our ability to develop and commercialize products, our ability to obtain required regulatory approvals, our compliance with all Food and Drug Administration regulations, our ability to obtain, maintain and protect intellectual property rights for our products, the risk of litigation regarding our intellectual property rights, our limited sales and manufacturing capabilities, our dependence on third-party manufacturers and value added resellers, our ability to hire and retain skilled personnel, our volatile stock price, and other risks detailed in Repligen's filings with the Securities and Exchange Commission. Repligen assumes no obligation to update any forward-looking information contained in this press release or with respect to the announcements d
'/>"/>
SOURCE Repligen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
2. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
3. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
4. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
5. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
6. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
7. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
8. RainDance Technologies to Present Sequence Enrichment Using Droplet-Based Microfluidics Workshop at ASHG 2008
9. SCOLR Pharma, Inc. to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
10. Nile Therapeutics to Present at Two Upcoming Investor Conferences
11. Arno Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2015)... , March 25, 2015 /PRNewswire/ - SQI Diagnostics Inc. ... that, as a result of recent discussions with certain ... shares of the Company, after dealing with certain matters ... special meeting of shareholders on March 26, 2015 (the ... the election of directors will take place when the ...
(Date:3/25/2015)... 25, 2015 Accelovance, a therapeutically focused contract ... "Best Contract Research Organization" at the upcoming Vaccine Industry ... This is the eighth consecutive year ... award, winning for "Best Contract Research Organization" in 2009, ... in 2013. "We,re excited to be a ...
(Date:3/25/2015)... IL (PRWEB) March 25, 2015 Having ... in the latter part of 2014, ITRA Global proudly ... Global, the International Tenant Representative Alliance, based in the ... to representing tenants and occupiers of commercial real estate. ... estate advisory firm in Poland that exclusively advises occupiers ...
(Date:3/25/2015)... , March 25, 2015  18 piglets born ... intense research by scientists in the College of Agriculture ... represent a breakthrough in the field of genetic ... the Department of Animal & Avian Sciences (ANSC) and ... ANSC, successfully produced genome-edited pigs using a recently ...
Breaking Biology Technology:SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 2SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 3SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 4SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 5Accelovance Nominated for 2015 Vaccine Industry Excellence (ViE) Awards 2International Organization Expands its Global Reach to Warsaw, Poland 2University of Maryland Researchers Successfully Produce Genome-edited Pigs Using Revolutionary Technology 2
... NEW YORK, April 16 NexGenix Pharmaceuticals, presented,data ... Annual Meeting of the AACR,in San Diego today. ... on NXD30001, one of several novel, radicicol-based,Hsp90 inhibitors ... in breast cancer tumor xenograft models,without evidence for ...
... April 16 Kosan Biosciences,Incorporated (Nasdaq: KOSN ... inhibitors demonstrating a high degree of target,specificity, strong ... tumor,tissue and significant antitumor activity and safety in ... protein chaperone that acts to stabilize and/or activate ...
... ROCKVILLE, Md., April 16 The Board of ... that Dr. Danong Chen has,been elected as the ... Chen,was previously the President and CEO of Tanox ... by Genentech in 2007.,Previously Dr. Chen was Vice-President ...
Cached Biology Technology:NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the Annual Meeting of the American Association for Cancer Research (AACR); Scientific Advisory Board Chairman Tyler Jacks Named President-elect 2NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the Annual Meeting of the American Association for Cancer Research (AACR); Scientific Advisory Board Chairman Tyler Jacks Named President-elect 3Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR 2Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR 3Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR 4Danong Chen appointed CEO of Theranostics Health 2
(Date:3/16/2015)... HANOVER, Germany , March 16, 2015 /PRNewswire/ ... DERMALOG Identification Systems GmbH will present groundbreaking innovations ... Hanover, Germany . ... DERMALOG,s latest biometric innovation is well at ... the next generation e-gate made in ...
(Date:3/12/2015)... March 12, 2015 Beta ... identity and access management (IAM) solution for a ... With Beta System,s new IAM package, customers benefit ... gleaned from multiple IAM implementations across different industries. ... as well as any necessary services and consulting. ...
(Date:3/11/2015)...   The Sync Project™ today announced ... and harness music to improve health. The platform ... measurements of physiology, enabling the study of the ... populations. It is designed for medical and health ... studies and accelerate the discovery of the clinical ...
Breaking Biology News(10 mins):DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 3
... of Chicago Celiac Disease Center is hosting the 15th ... in Chicago. The symposium is the largest celiac disease ... which follows the 2011 conference in Oslo, Norway, is ... since 2006. The Chicago meeting seeks to address ...
... a continued increase in the proportion of its journal titles indexed ... JCR ), with 1,192 (approximately 77%) titles now indexed, up from ... largest share of journals in 50 categories. In the ... rank increased by 19% (4) and the number of Wiley titles ...
... Cancer Research Group (ACRG), an independent, not-for-profit company in ... The University of Hong Kong (HKU), jointly announced the ... in hepatocellular carcinoma (HCC), one of the most deadly ... . The study provides new insights into potential therapeutic ...
Cached Biology News:UChicago Celiac Disease Center to host international symposium 2Wiley announces increase in Impact Factors 2Wiley announces increase in Impact Factors 3Wiley announces increase in Impact Factors 4Wiley announces increase in Impact Factors 5Wiley announces increase in Impact Factors 6ACRG and BGI report new evidence for the genetic bases of liver cancer 2
... atoms at the 9, 10, 12, and 13 ... internal standard for the quantification of 13(S)-HODE by ... incubation of linoleic acid with plant and mammalian ... adhesion of tumor cells to the endothelium at ...
...
...
...
Biology Products: